Aquestive Therapeutics Inc
NASDAQ:AQST
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.59
6.09
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AQST stock under the Base Case scenario is 2.0795 USD. Compared to the current market price of 4.6946 USD, Aquestive Therapeutics Inc is Overvalued by 56%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Aquestive Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AQST cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Aquestive Therapeutics Inc
Balance Sheet Decomposition
Aquestive Therapeutics Inc
Current Assets | 104m |
Cash & Short-Term Investments | 89.9m |
Receivables | 6m |
Other Current Assets | 8.1m |
Non-Current Assets | 13.6m |
PP&E | 9.4m |
Other Non-Current Assets | 4.2m |
Current Liabilities | 13.9m |
Accounts Payable | 5.7m |
Accrued Liabilities | 6.1m |
Other Current Liabilities | 2.1m |
Non-Current Liabilities | 139.2m |
Long-Term Debt | 30m |
Other Non-Current Liabilities | 109.2m |
Earnings Waterfall
Aquestive Therapeutics Inc
Revenue
|
58.4m
USD
|
Cost of Revenue
|
-18.4m
USD
|
Gross Profit
|
40m
USD
|
Operating Expenses
|
-55.2m
USD
|
Operating Income
|
-15.2m
USD
|
Other Expenses
|
-10.5m
USD
|
Net Income
|
-25.7m
USD
|
Free Cash Flow Analysis
Aquestive Therapeutics Inc
USD | |
Free Cash Flow | USD |
AQST Profitability Score
Profitability Due Diligence
Aquestive Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Aquestive Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
AQST Solvency Score
Solvency Due Diligence
Aquestive Therapeutics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Aquestive Therapeutics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AQST Price Targets Summary
Aquestive Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AQST is 9.6263 USD with a low forecast of 5.555 USD and a high forecast of 15.75 USD.
Dividends
Current shareholder yield for AQST is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.
Contact
IPO
Employees
Officers
The intrinsic value of one AQST stock under the Base Case scenario is 2.0795 USD.
Compared to the current market price of 4.6946 USD, Aquestive Therapeutics Inc is Overvalued by 56%.